Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Rhythmia Medical

Request full access

Rhythmia Medical develops medical devices for the treatment of cardiac arrhythmia

Burlington, United StatesFounded 2004Health Tech & Medtech

About Rhythmia Medical

Rhythmia Medical, Inc. operated as a developer of advanced medical technology focused on cardiac rhythm disorders. The company was founded in 2004 by business school graduates Leon Amariglio and Doron Harlev, who aimed to build a business with a positive societal impact by creating their own technology.

The core of Rhythmia Medical's business was the development of a next-generation 3D mapping and navigation system for use in cardiac catheter ablation procedures. This system was created to treat tachy-arrhythmias, which are rapid, irregular heartbeats such as atrial fibrillation and atrial flutter. These conditions affect approximately 15 million people worldwide. The company's primary clients were physicians and hospitals specializing in electrophysiology.

Rhythmia's product consisted of a two-part system designed to provide physicians with a clearer, three-dimensional picture of the heart's architecture and electrical activity as it beats. The first component was a specialized catheter featuring 64 electrodes to track electrical signals and map the heart's internal geometry. The second part was sophisticated software that translated the vast amount of data collected by the catheter into detailed 3D visualizations. This high-resolution mapping was intended to help physicians more accurately identify the source of irregular heartbeats, significantly improving the precision and efficiency of ablation procedures. In pre-clinical and clinical tests, the system demonstrated the ability to reduce heart mapping time by at least half.

The company's journey included securing at least $17 million in venture capital funding and receiving a grant from the National Institutes of Health. A significant milestone occurred in October 2012, when Boston Scientific Corporation entered into a definitive agreement to acquire Rhythmia Medical. The acquisition was a strategic move for Boston Scientific to enter the $2.5 billion electrophysiology market. The deal included an upfront payment of $90 million, with up to an additional $175 million in contingent payments based on regulatory, commercial, and sales-based milestones through 2017. Following the acquisition, the technology was further developed and commercialized as the RHYTHMIA™ Mapping System.

Source: Dealroom company data

Rhythmia Medical in the Burlington ecosystem

Live from Dealroom

The Rhythmia Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Norwich Ventures
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Burlington HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Rhythmia Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rhythmia Medical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.